Top 11 CRISPR Stocks to Invest In

Page 8 of 10

3. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 27

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneering leader in gene-editing technology, leveraging its proprietary gene sequencing platform to develop precise DNA modification therapies for serious diseases.

The company’s recent launch of Casgevy and its expanding pipeline have drawn significant attention from investors and analysts. To date, CRISPR Therapeutics AG (NASDAQ:CRSP) has activated over 35 Authorized Treatment Centers globally, reflecting a substantial increase from prior quarters.

Operating in a rapidly expanding market projected to grow at an annual rate of 22.3% from 2022 to 2027, CRISPR Therapeutics AG (NASDAQ:CRSP) is poised to capture a significant share of the gene-editing industry, expected to reach a total value of $9.2 billion. Over the past year, the company reported revenue exceeding $200 million, bolstered by substantial royalty payments, particularly from Vertex Pharmaceuticals for a sickle cell treatment.

Page 8 of 10